RESUMO
We report the first manifestation of mania in an 85-year-old patient who had not previously received any psychiatric treatment. The patient had had Alzheimer's type dementia for 3 years. The COVID-19 infection took a mild course in accordance with the RKI guidelines. This was followed by a manic syndrome according to the ICD-10 with a clearly elevated mood, increased drive and behavior that occured for the first time in the patient's life.
Assuntos
Transtorno Bipolar , COVID-19 , Idoso de 80 Anos ou mais , Alemanha , Humanos , Mania , SARS-CoV-2RESUMO
The implementation of ECT treatment should not be ruled out in principle even if there is a cavernoma of the medulla oblongata with previous bleeding, but it requires appropriate conditions such as neurosurgical consultation, strict blood pressure monitoring and special information from the patient.
Assuntos
Eletroconvulsoterapia , Feminino , Humanos , BulboRESUMO
Hypersexual behavior can be assumed as a rare side effect of treatment with aripiprazole and is possibly due to partial agonism on dopamine receptors or partial agonism on 5-HT1A receptors and 5 HT2A antagonism.
Assuntos
Antipsicóticos , Aripiprazol , Comportamento Sexual , Disfunções Sexuais Psicogênicas/induzido quimicamente , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Aripiprazol/efeitos adversos , Aripiprazol/uso terapêutico , Alemanha , Humanos , Receptor 5-HT1A de Serotonina , Receptor 5-HT2A de Serotonina , Antagonistas do Receptor 5-HT2 de Serotonina , Disfunções Sexuais Psicogênicas/psicologiaRESUMO
Disturbances of thermoregulation are a well-known side effect of neuroleptic treatment, especially hyperthermia. Hypothermia can occur also during treatment with neuroleptics. Now hypothermia is more and more due to atypical neuroleptics in relation to 5-HT2A antagonism. We report the case of a patient (92 years) suffering from dementia with a hypothermia during treatment with aripiprazole.
Assuntos
Antipsicóticos/efeitos adversos , Aripiprazol/efeitos adversos , Hipotermia/epidemiologia , Quimioterapia Combinada , Alemanha , HumanosRESUMO
We report the case of a 24 year old man, suffering from schizophrenia who has an frontobasal osteosynthesis after an attempted suicide by jumping from a bridge. He received 14 treatments of electroconvulsive therapy (ECT), the electrode position was right unilateral. The treatment was successful and without any complications. Although the patient received a neuroleptic treatment before, he had florid positive symptoms. Hence, we considered ECT as a helpful treatment. The patient and also his legal guardian gave a written informed consent. The ECT was carried out during his stay in a forensic hospital. We therefore consider ECT a secure treatment in this case.
Assuntos
Antipsicóticos , Eletroconvulsoterapia , Esquizofrenia/terapia , Adulto , Alemanha , Humanos , Masculino , Titânio , Adulto JovemRESUMO
A 58 years old woman with a depression showed a QTc prolongation during treatment with agomelatine which was fully reversible after stopping administration. QTc prolongation during antidepressant treatment is not unknown especially when tricyclic antidepressants are administered. This case is the first occurrence of a QTc prolongation during treatment with agomelatine.
Assuntos
Acetamidas/efeitos adversos , Antidepressivos/efeitos adversos , Transtorno Depressivo/tratamento farmacológico , Síndrome do QT Longo/induzido quimicamente , Acetamidas/uso terapêutico , Antidepressivos/uso terapêutico , Relação Dose-Resposta a Droga , Esquema de Medicação , Eletrocardiografia/efeitos dos fármacos , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
Following ten years of continuous olanzapine therapy a 51 years old man developed a Gilles de la Tourette syndrome which disappeared after changing to amisulprid. The Tourette-syndrome will be attributed to a tardive dyskinesia induced by olanzapine.
Assuntos
Antipsicóticos/efeitos adversos , Discinesia Induzida por Medicamentos/diagnóstico , Prometazina/efeitos adversos , Síndrome de Tourette/induzido quimicamente , Amissulprida , Antipsicóticos/uso terapêutico , Benzodiazepinas/administração & dosagem , Benzodiazepinas/uso terapêutico , Quimioterapia Combinada , Discinesia Induzida por Medicamentos/tratamento farmacológico , Humanos , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Olanzapina , Prometazina/uso terapêutico , Sulpirida/análogos & derivados , Sulpirida/uso terapêutico , Síndrome de Tourette/diagnóstico , Síndrome de Tourette/tratamento farmacológico , Comportamento Verbal/efeitos dos fármacosAssuntos
Transtornos Psicóticos Afetivos/tratamento farmacológico , Antidepressivos/uso terapêutico , Delusões/tratamento farmacológico , Despersonalização/tratamento farmacológico , Transtorno Depressivo Maior/tratamento farmacológico , Tiofenos/uso terapêutico , Transtornos Psicóticos Afetivos/diagnóstico , Transtornos Psicóticos Afetivos/psicologia , Idoso , Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Citalopram/uso terapêutico , Delusões/diagnóstico , Delusões/psicologia , Despersonalização/diagnóstico , Despersonalização/psicologia , Transtorno Depressivo Maior/diagnóstico , Transtorno Depressivo Maior/psicologia , Quimioterapia Combinada , Cloridrato de Duloxetina , Feminino , Humanos , Assistência de Longa Duração , Olanzapina , Risperidona/uso terapêutico , SíndromeRESUMO
The serotonin-syndrome is a possible side-effect in the treatment with serotonergic drugs. There are diagnostic criteria for diagnosis of this syndrome. After discontinuation of administering the serotonergic drug is fully reversible.
Assuntos
Serotoninérgicos/efeitos adversos , Síndrome da Serotonina/diagnóstico , Idoso , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Citalopram/efeitos adversos , Citalopram/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Dibenzotiepinas/efeitos adversos , Dibenzotiepinas/uso terapêutico , Relação Dose-Resposta a Droga , Interações Medicamentosas , Quimioterapia Combinada , Feminino , Humanos , Pessoa de Meia-Idade , Exame Neurológico , Paroxetina/efeitos adversos , Paroxetina/uso terapêutico , Recidiva , Serotoninérgicos/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Inibidores Seletivos de Recaptação de Serotonina/uso terapêuticoRESUMO
According to most diagnostic manuals such as ICD-10 and DSM-IV, kleptomania is classified as an impulse-control disorder. With regard to comorbidity, kleptomania is related to the obsessive- compulsive disorder spectrum and to the broader spectrum of affective disorders. Accordingly a psychopharmacological intervention with anti-depressant drugs or mood stabilizers may be possible, even though there are to date no known results from controlled therapy studies. Nevertheless the successful administration of such medication has been reported in several cases. Assuming a disturbed central serotonin reuptake, the use of selective serotonin reuptake inhibitors (SSRI) seems to be indicated. But also naltrexone could be of use in kleptomania.
Assuntos
Transtornos Disruptivos, de Controle do Impulso e da Conduta/tratamento farmacológico , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Transtornos Disruptivos, de Controle do Impulso e da Conduta/diagnóstico , Transtornos Disruptivos, de Controle do Impulso e da Conduta/psicologia , Humanos , Resultado do TratamentoAssuntos
Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Dor no Peito/psicologia , Fadiga/psicologia , Dor/psicologia , Transtornos Somatoformes/tratamento farmacológico , Clomipramina/uso terapêutico , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/tratamento farmacológico , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Couro Cabeludo , Transtornos Somatoformes/diagnósticoRESUMO
A potential side-effect in the treatment with olanzapine is hyperglycemia or new onset diabetes mellitus. There are possible mechanisms by which olanzapine could interfere with glucose metabolism but decreased insulin sensitivity due to weight gain is of most relevance.